Early successes and late failures in the prevention of post endoscopic retrogade cholangiopancreatography

World Journal of Gastroenterology

Volumn 13, Issue 26, 2007, Pages 3567-3574

  Lieb II, John G ^a   Draganov, Peter V ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Aspirating catheter; Gabexate; IL 10; Pancreatic stents; Post endoscopic retrograde cholangiopancreatography pancreatitis; Somatostatin; Sphincter of Oddi dysfunction

Indexed keywords

ACETYLCYSTEINE; ADRENALIN; ALLOPURINOL; APROTININ; BETA CAROTENE; BOTULINUM TOXIN; CALCITONIN; CERTOPARIN; CONTRAST MEDIUM; CORTICOSTEROID; DICLOFENAC; FLUOROURACIL; GABEXATE; GLUCAGON; GLYCERYL TRINITRATE; HEPARIN; INTERLEUKIN 10; ISONIAZID DERIVATIVE; LIDOCAINE; LOW MOLECULAR WEIGHT HEPARIN; NIFEDIPINE; NITRIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; PLACEBO; SECRETIN; SOMATOSTATIN; STEROID; ULINASTATIN; UNINDEXED DRUG;

ACUTE PANCREATITIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CANNULATION; CAUTERIZATION; CLINICAL DECISION MAKING; CLINICAL TRIAL; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG TREATMENT FAILURE; ELECTROSURGERY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; NONHUMAN; PANCREAS DUCT; PANCREATITIS; PATIENT POSITIONING; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SINGLE DRUG DOSE; SPHINCTEROTOMY; STENT; SURGICAL INSTRUMENT; TRANSDERMAL PATCH; TREATMENT INDICATION; VATER PAPILLA STENOSIS;

EID: 34547445003     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i26.3567     Document Type: Article

References (88)

1. Cotton PB, Lehman G, Vennes J, Geenen JE, Russell RC, Meyers WC, Liguory C, Nickl N. Endoscopic sphincterotomy complications and their management an attempt at consensus. Gastrointest Endosc 1991; 37: 383-393
2. Freeman ML, Nelson DB, Sherman S, Haber GB, Herman ME, Dorsher PJ, Moore JP, Fennerty MB, Ryan ME, Shaw MJ, Lande JD, Pheley AM. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996; 335: 909-918
3. Cheon YK, Cho KB, Watkins JL, McHenry L, Fogel EL, Sherman S, Lehman GA. Frequency and severity of post-ERCP pancreatitis correlated with extent of pancreatic ductal opacification. Gastrointest Endosc 2007; 65: 385-393
4. Freeman ML, DiSario JA, Nelson DB, Fennerty MB, Lee JG, Bjorkman DJ, Overby CS, Aas J, Ryan ME, Bochna GS, Shaw MJ, Snady HW, Erickson RV, Moore JP, Roel JP. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 2001; 54: 425-434
5. Rabenstein T, Framke B, Martus P, et al. Method related risk factors for complications of endoscopic sphincterotomy. A prospective study (abstract). Gastrointest Endosc 1999; 49: AB 73
6. Loperfido S, Angelini G, Benedetti G, Chilovi F, Costan F, De Berardinis F, De Bernardin M, Ederle A, Fina P, Fratton A. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc 1998; 48: 1-10
7. Foster E, Leung J. Pharmacotherapy for the prevention of post-ERCP pancreatitis. Am J Gastroenterol 2007; 102: 52-55
8. Pezzilli R, Romboli E, Campana D, Corinaldesi R. Mechanisms involved in the onset of post-ERCP pancreatitis. JOP 2002; 3: 162-168
9. Cotton PB. Analysis of 59 ERCP lawsuits; mainly about indications. Gastrointest Endosc 2006; 63: 378-382; quiz 464
10. Tamas G Jr, Tulassay Z, Papp J, Paksy A, Koranyi L, Kisfaludy S, Kollin E, Steczek K. Effect of somatostatin on the pancreatitis-like biochemical changes due to endoscopic pancreatography: preliminary report. Metabolism 1978; 27: 1333-1336
11. Testoni PA. Facts and fiction in the pharmacologic prevention of post-ERCP pancreatitis: a never-ending story. Gastrointest Endosc 2006; 64: 732-734
12. Thomopoulos KC, Pagoni NA, Vagenas KA, Margaritis VG, Theocharis GI, Nikolopoulou VN. Twenty-four hour prophylaxis with increased dosage of octreotide reduces the incidence of post-ERCP pancreatitis. Gastrointest Endosc 2006; 64: 726-731
13. Binmoeller KF, Dumas R, Harris AG, Delmont JP. Effect of somatostatin analog octreotide on human sphincter of Oddi. Dig Dis Sci 1992; 37: 773-777
14. Poon RT, Fan ST. Antisecretory agents for prevention of post-ERCP pancreatitis: rationale for use and clinical results, JOP 2003; 4: 33-40
15. Andriulli A, Leandro G, Niro G, Mangia A, Festa V. Gambassi G, Villani MR, Facciorusso D, Conoscitore P, Spirito F, De Maio G. Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. Gastrointest Endosc 2000; 51: 1-7
16. Andriulli A, Caruso N, Quitadamo M, Forlano R, Leandro G, Spirito F, De Maio G. Antisecretory vs. antiproteasic drugs in the prevention of post-ERCP pancreatitis: the evidence-based medicine derived from a meta-analysis study. JOP 2003; 4: 41-48
17. Lung E. The use of somatostatin or octreotide to prevent post ERCP pancreatitis, a meta analysis of randomized controlled trials [abstract]. Gastrointest Endosc 2004; 59: AB 107
18. Li ZS, Pan X, Zhang WJ, Gong B, Zhi FC, Guo XG, Li PM, Fan ZN, Sun WS, Shen YZ, Ma SR, Xie WF, Chen MH, Li YQ. Effect of octreotide administration in the prophylaxis of post-ERCP pancreatitis and hyperamylasemia: A multicenter, placebo-controlled, randomized clinical trial. Am J Gastroenterol 2007; 102: 46-51
19. Pereira SP, Gillams A, Sgouros SN, Webster GJ, Hatfield AR. Prospective comparison of secretin-stimulated MRCP with manometry in the diagnosis of sphincter of Oddi dysfunction types II and III. Gut, online. 2006 Sep 27
20. Mundorf J, Jowell P, Branch M, Affronti J, Cotton P, and Baillie J. Reduced incidence of post ERCP pancreatitis in non-pancreas divisum patients who receive IV secretin during ERCP. (abstract) Am J Gastroenter 1995; 90: 1611
21. Tympner F, Rosch W. Effect of secretin and gabexate-mesilate (synthetic protease inhibitor) on serum amylase level after ERCP. Z Gastroenterol 1982; 20: 688-693
22. Schapiro H, Ludewig RM. The effect of glucagon on the exocrine pancreas. A review. Am J Gastroenterol 1978; 70: 274-281
23. Dalal PU, Howlett DC, Sallomi DF, Marchbank ND, Watson GM, Marr A, Dunk AA, Smith AD. Does intravenous glucagon improve common bile duct visualisation during magnetic resonance cholangiopancreatography? Results in 42 patients. Eur J Radiol 2004; 49: 258-261
24. Silvis SE, Vennes JA. The role of glucagon in endoscopic cholangiopancreatography. Gastrointest Endosc 1975; 21: 162-163
25. Odes HS, Barbezat GO, Clain JE, Bank S. The effect of calcitonin on secretin-stimulated pancreatic secretion in man. S Afr Med J 1978; 53: 201-203
26. Odes HS, Novis BN, Barbezat GO, Bank S. Effect of calcitonin on the serum amylase levels after endoscopic retrograde cholangiopancreatography. Digestion 1977; 16: 180-184
27. Brandes JW, Scheffer B, Lorenz-Meyer H, Korst HA, Littmann KP. ERCP: Complications and prophylaxis a controlled study. Endoscopy 1981; 13: 27-30
28. Sudhindran S, Bromwich E, Edwards PR. Prospective randomized double-blind placebo-controlled trial of glyceryl trinitrate in endoscopic retrograde cholangiopancreatography-induced pancreatitis. Br J Surg 2001; 88: 1178-1182
29. Moreto M, Zaballa M, Casado I. Transdermal glyceryl trinitrate for prevention of post ERCP pancreatitis: a randomized, double blind trial. Gastrointest Endosc. 2003: 57: 1-7
30. Muralidharan V, Jamidar P. Pharmacologic prevention of post-ERCP pancreatitis: is nitroglycerin a sangreal? Gastrointest Endosc 2006; 64: 358-360
31. Kaffes AJ, Bourke MJ, Ding S, Alrubaie A, Kwan V, Williams SJ. A prospective, randomized, placebo-controlled trial of transdermal glyceryl trinitrate in ERCP: effects on technical success and post-ERCP pancreatitis. Gastrointest Endosc 2006; 64: 351-357
32. Sand I, Nordback I. Prospective randomized trial of the effect of nifedipine on pancreatic irritation after ERCP. Digestion 1993; 54: 105
33. Prat F, Amaris J, Ducot B, Bocquentin M, Fritsch J, Choury AD, Pelletier G, Buffet C. Nifedipine for prevention of post-ERCP pancreatitis: a prospective, double-blind randomized study. Gastrointest Endosc 2002; 56: 202-208
34. Schwartz JJ, Lew RJ, Ahmad NA, Shah JN, Ginsberg GG, Kochman ML, Brensinger CM, Long WB. The effect of lidocaine sprayed on the major duodenal papilla on the frequency of post-ERCP pancreatitis. Gastrointest Endosc 2004; 59: 179-184
35. Gorelick A, Barnett J, Chey W, Anderson M, Elta G. Botulinum toxin injection after biliary sphincterotomy. Endoscopy 2004; 36: 170-173
36. Wehrmann T. Sphincter of Oddi dysfunction: cut and inject, but don't measure the pressure? Endoscopy 2004; 36: 179-182
37. Cotton PB, Hawes RH. Botulinum toxin injection after biliary sphincterotomy. Endoscopy 2004; 36: 744; author reply 745
38. Ohashi A, Tamada K, Tomiyama T, Wada S, Higashizawa T, Gotoh Y, Satoh Y, Miyata T, Tano S, Ido K, Sugano K. Epinephrine irrigation for the prevention of pancreatic damage after endoscopic balloon sphincteroplasty. J Gastroenterol Hepatol 2001; 16: 568-571
39. Weiner GR, Geenen JE, Hogan WJ, Catalano MF. Use of corticosteroids in the prevention of post-ERCP pancreatitis. Gastrointest Endosc 1995; 42: 579-583
40. Sherman S, Lehman GA, Earle DE, Watkins M, Freeman H. Does prophylactic steroid administration reduce the frequency and severity of post-ERCP pancreatitis? Randomized prospective multicenter study (abstract). Gastrointest Endosc 1996; 43: 320
41. Dumot JA, Conwell DL, O'Connor JB, Ferguson DR, Vargo JJ, Barnes DS, Shay SS, Sterling MJ, Horth KS, Issa K, Ponsky JL, Zuccaro G. Pretreatment with methylprednisolone to prevent ERCP-induced pancreatitis: a randomized, multicenter, placebo-controlled clinical trial. Am J Gastroenterol 1998; 93: 61-65
42. Sherman S, Blaut U, Watkins JL, Barnett J, Freeman M, Geenen J, Ryan M, Parker H, Frakes JT, Fogel EL, Silverman WB, Dua KS, Aliperti G, Yakshe P, Uzer M, Jones W, Goff J, Earle D, Temkit M, Lehman GA. Does prophylactic administration of corticosteroid reduce the risk and severity of post-ERCP pancreatitis: a randomized, prospective, multicenter study. Gastrointest Endosc 2003; 58: 23-29
43. Van Laethem JL, Marchant A, Delvaux A, Goldman M, Robberecht P, Velu T, Deviere J. Interleukin 10 prevents necrosis in murine experimental acute pancreatitis. Gastroenterology 1995; 108: 1917-1922
44. Deviere J, Le Moine O, Van Laethem JL, Eisendrath P, Ghilain A, Severs N, Cohard M. Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography. Gastroenterology 2001; 120: 498-505
45. Dumot JA, Conwell DL, Zuccaro G Jr, Vargo JJ, Shay SS, Easley KA, Ponsky JL. A randomized, double blind study of interleukin 10 for the prevention of ERCP-induced pancreatitis. Am J Gastroenterol 2001; 96: 2098-2102
46. Fan WT, Wang QW, Li QL. Preventive effect of 5-fluorouracil on post-ERCP pancreatitis. Zhongnan Daxue Xuebao Yixueban 2004; 29: 201-203
47. Murray B, Carter R, Imrie C, Evans S, O'Suilleabhain C. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology 2003; 124: 1786-1791
48. Freeman ML. Prevention of post-ERCP pancreatitis: pharmacologic solution or patient selection and pancreatic stents? Gastroenterology 2003; 124: 1977-1980
49. Sato K, Yamada E, Uehara Y, Takagi H, Mori M. Possible role for human leukocyte antigen haplotype in rofecoxib-associated acute pancreatitis and cholestatic hepatitis. Clin Pharmacol Ther 2006; 80: 554-555
50. Sorensen HT, Jacobsen J, Norgaard M, Pedersen L, Johnsen SP, Baron JA. Newer cyclo-oxygenase-2 selective inhibitors, other non-steroidal anti-inflammatory drugs and the risk of acute pancreatitis. Aliment Pharmacol Ther 2006; 24: 111-116
51. Rabenstein T, Roggenbuck S, Framke B, Martus P, Fischer B, Nusko G, Muehldorfer S, Hochberger J, Ell C, Hahn EG, Schneider HT. Complications of endoscopic sphincterotomy: can heparin prevent acute pancreatitis after ERCP? Gastrointest Endosc 2002; 55: 476-483
52. Rabenstein T, Fischer B, Wiessner V, Schmidt H, Radespiel-Troger M, Hochberger J, Muhldorfer S, Nusko G, Messmann H, Scholmerich J, Schulz HJ, Schonekas H, Hahn EG, Schneider HT. Low-molecular-weight heparin does not prevent acute post-ERCP pancreatitis. Gastrointest Endosc 2004; 59: 606-613
53. Katsinelos P, Kountouras J, Chatzis J, Christodoulou K, Paroutoglou G, Mimidis K, Beltsis A, Zavos C. High-dose allopurinol for prevention of post-ERCP pancreatitis: a prospective randomized double-blind controlled trial. Gastrointest Endosc 2005; 61: 407-415
54. Budzynska A, Marek T, Nowak A, Kaczor R, Nowakowska-Dulawa E. A prospective, randomized, placebo-controlled trial of prednisone and allopurinol in the prevention of ERCP-induced pancreatitis. Endoscopy 2001; 33: 766-772
55. Mosler P, Sherman S, Marks J, Watkins JL, Geenen JE, Jamidar P, Fogel EL, Lazzell-Pannell L, Temkit M, Tarnasky P, Block KP, Frakes JT, Aziz AA, Malik P, Nickl N, Slivka A, Goff J, Lehman GA. Oral allopurinol does not prevent the frequency or the severity of post-ERCP pancreatitis. Gastrointest Endosc 2005; 62: 245-250
56. Katsinelos P, Kountouras J, Paroutoglou G, Beltsis A, Mimidis K, Zavos C. Intravenous N-acetylcysteine does not prevent post-ERCP pancreatitis. Gastrointest Endosc 2005; 62: 105-111
57. Wollschlager S, Patzold K, Bulang T, Meissner D, Porst H. Effect of preventive selenium administration on development of ERCP-induced acute pancreatitis. Med Kiln (Munich) 1999; 94 Suppl 3: 81-83
58. Lavy A, Karban A, Suissa A, Yassin K, Hermesh I, Ben-Amotz A. Natural beta-carotene for the prevention of post-ERCP pancreatitis. Pancreas 2004; 29: e45-e50
59. Brust R, Thomson AB, Wensel RH, Sherbaniuk RW, Costopoulos L. Pancreatic injury following ERCP. Failure of prophylactic benefit of Trasylol. Gastrointest Endosc 1977; 24: 77-79
60. Testoni PA, Cicardi M, Bergamaschini L, Guzzoni S, Cugno M, Buizza M, Bagnolo F, Agostoni A. Infusion of C1-inhibitor plasma concentrate prevents hyperamylasemia induced by endoscopic sphincterotomy. Gastrointest Endosc 1995; 42: 301-305
61. Matsukawa H, Hara A, Ito T, Fukui K, Sato K, Ichikawa M, Yoshioka M, Seki H, Yamataka K, Takizawa K, Okuda S, Shiraga N. Continuous arterial infusion of protease inhibitor with supplementary therapy for the patients with severe acute pancreatitis - clinical effect of arterial injection of ulinastatin. Nippon Shokakibyo Gakkai Zasshi 1998; 95: 1229-1234
62. Tsujino T, Komatsu Y, Isayama H, Hirano K, Sasahira N, Yamamoto N, Toda N, Ito Y, Nakai Y, Tada M, Matsumura M, Yoshida H, Kawabe T, Shiratori Y, Omata M. Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial. Clin Gastroenterol Hepatol 2005; 3: 376-383
63. Tamura Y, Hirado M, Okamura K, Minato Y, Fujii S. Synthetic inhibitors of trypsin, plasmin, kallikrein, thrombin, Clr-, and C1 esterase. Biochim Biophys Acta 1977; 484: 417-422
64. Cavallini G, Tittobello A, Frulloni L, Masci E, Mariana A, Di Francesco V. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy-Italian Group. N Engl J Med 1996; 335: 919-923
65. Xiong GS, Wu SM, Zhang XW, Ge ZZ. Clinical trial of gabexate in the prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis. Braz J Med Biol Res 2006; 39: 85-90
66. Andriulli A, Clemente R, Solmi L, Terruzzi V, Suriani R, Sigillito A, Leandro G, Leo P, De Maio G, Perri F. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc 2002; 56: 488-495
67. Andriulli A, Solmi L, Loperfido S, Leo P, Festa V, Belmonte A, Spirito F, Silla M, Forte G, Terruzzi V, Marenco G, Ciliberto E, Sabatino A, Monica F, Magnolia MR, Perri F. Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate. Clin Gastroenterol Hepatol 2004; 2: 713-718
68. Andriulli A, Leandro G, Federici T, Ippolito A, Forlano R, Iacobellis A, Annese V. Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis. Gastrointest Endosc 2007; 65: 624-632
69. Sherman S, Troiano FP, Hawes RH, Lehman GA. Sphincter of Oddi manometry: decreased risk of clinical pancreatitis with use of a modified aspirating catheter. Gastrointest Endosc 1990; 36: 462-466
70. Lella F, Bagnolo F, Colombo E, Bonassi U. A simple way of avoiding post-ERCP pancreatitis. Gastrointest Endosc 2004; 59: 830-834
71. Elta GH, Barnett JL, Wille RT, Brown KA, Chey WD, Scheiman JM. Pure cut electrocautery current for sphincterotomy causes less post-procedure pancreatitis than blended current Gastrointest Endosc 1998; 47: 149-153
72. Macintosh DG, Love J, Abraham NS. Endoscopic sphincterotomy by using pure-cut electrosurgical current and the risk of post-ERCP pancreatitis: a prospective randomized trial. Gastrointest Endosc 2004; 60: 551-556
73. Stefanidis G, Karamanolis G, Viazis N, Sgouros S, Papadopoulou E, Ntatsakis K, Mantides A, Nastos H. A comparative study of postendoscopic sphincterotomy complications with various types of electrosurgical current in patients with choledocholithiasis. Gastrointest Endosc 2003; 57: 192-197
74. Perini RF, Sadurski R, Cotton PB, Patel RS, Hawes RH, Cunningham JT. Post-sphincterotomy bleeding after the introduction of microprocessor-controlled electrosurgery: does the new technology make the difference? Gastrointest Endosc 2005; 61: 53-57
75. Norton ID, Petersen BT, Bosco J, Nelson DB, Meier PB, Baron TH, Lange SM, Gostout CJ, Loeb DS, Levy MJ, Wiersema MJ, Pochron N. A randomized trial of endoscopic biliary sphincterotomy using pure-cut versus combined cut and coagulation waveforms. Clin Gastroenterol Hepatol 2005; 3: 1029-1033
76. Cunliffe WJ, Cobden I, Lavelle MI, Lendrum R, Tait NP, Venables CW. A randomised, prospective study comparing two contrast media in ERCP. Endoscopy 1987; 19: 201-202
77. George S, Kulkarni AA, Stevens G, Forsmark CE, Draganov P. Role of osmolality of contrast media in the development of post-ERCP pancreatitis: a metanalysis. Dig Dis Sci 2004; 49: 503-508
78. Leung JW, Vallero R, Chin A. Prevention of post ERCP pancreatitis by patient positioning. Gastrointest Endosc. 2002; 55 Abstract: 156-157
79. Smithline A, Silverman W, Rogers D, Nisi R, Wiersema M, Jamidar P, Hawes R, Lehman G. Effect of prophylactic main pancreatic duct stenting on the incidence of biliary endoscopic sphincterotomy-induced pancreatitis in high-risk patients. Gastrointest Endosc 1993; 39: 652-657
80. Sherman S, Earle D, Bucksot L. Does leaving a main pancreatic duct stent in place reduce the incidence of precut biliary sphincterotomy (ES)-induced pancreatitis? A final analysis of a randomized prospective study (abstract). Gastrointest Endosc 1996; 43: 413A
81. Tarnasky PR, Palesch YY, Cunningham JT, Mauldin PD, Cotton PB, Hawes RH. Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients with sphincter of Oddi dysfunction. Gastroenterology 1998; 115: 1518-1524
82. Fazel A, Quadri A, Catalano MF, Meyerson SM, Geenen JE. Does a pancreatic duct stent prevent post-ERCP pancreatitis? A prospective randomized study. Gastrointest Endosc 2003; 57: 291-294
83. Singh P, Das A, Isenberg G, Wong RC, Sivak MV Jr, Agrawal D, Chak A. Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials. Gastrointest Endosc 2004; 60: 544-550
84. Kozarek RA. Pancreatic stents can induce ductal changes consistent with chronic pancreatitis. Gastrointest Endosc 1990; 36: 93-95
85. Sherman S, Hawes RH, Savides TJ, Gress FG, Ikenberry SO, Smith MT, Zaidi S, Lehman GA. Stent-induced pancreatic ductal and parenchymal changes: correlation of endoscopic ultrasound with ERCP. Gastrointest Endosc 1996; 44: 276-282
86. Shakoor T, Hogan WJ, Geenen JE. Efficacy of nasopancreatic catheter in the prevention of post-ERCP pancreatitis: A prospective randomized controlled trial (abstract). Gastrointest Endosc 1992; 38: 251A
87. Elton E, Howell DA, Parsons WG, Qaseem T, Hanson BL. Endoscopic pancreatic sphincterotomy: indications, outcome, and a safe stentless technique. Gastrointest Endosc 1998; 47: 240-249
88. Rashdan A, Fogel EL, McHenry L Jr, Sherman S, Temkit M, Lehman GA. Improved stent characteristics for prophylaxis of post-ERCP pancreatitis. Clin Gastroenterol Hepatol 2004; 2: 322-329